CASZ1 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Xing-Biao Qiu,Xin-Kai Qu,Ruo-Gu Li,Hua Liu,Ying-Jia Xu,Min Zhang,Hong-Yu Shi,Xu-Min Hou,Xu Liu,Fang Yuan,Yu-Min Sun,Jun Wang,Ri-Tai Huang,Song Xue,Yi-Qing Yang
DOI: https://doi.org/10.1515/cclm-2016-0612
2017-01-01
Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract:Background: The zinc finger transcription factor CASZ1 plays a key role in cardiac development and postnatal adaptation, and in mice, deletion of the CASZ1 gene leads to dilated cardiomyopathy (DCM). However, in humans whether genetically defective CASZ1 contributes to DCM remains unclear.Methods: The coding exons and splicing junction sites of the CASZ1 gene were sequenced in 138 unrelated patients with idiopathic DCM. The available family members of the index patient harboring an identified CASZ1 mutation and 200 unrelated, ethnically matched healthy individuals used as controls were genotyped for CASZ1. The functional characteristics of the mutant CASZ1 were analyzed in contrast to its wild-type counterpart using a luciferase reporter assay system.Results: A novel heterozygous CASZ1 mutation, p. K351X, was identified in an index patient with DCM. Genetic analysis of the mutation carrier's family showed that the mutation co-segregated with DCM, which was transmitted in an autosomal dominant pattern with complete penetrance. The nonsense mutation, which was absent in 400 referential chromosomes, altered the amino acid that was highly conserved evolutionarily. Biological investigations revealed that the mutant CASZ1 had no transcriptional activity.Conclusions: The current study reveals CASZ1 as a new gene responsible for human DCM, which provides novel mechanistic insight and potential therapeutic target for CASZ1-associated DCM, implying potential implications in improved prophylactic and therapeutic strategies for DCM, the most common type of primary myocardial disease.
What problem does this paper attempt to address?